Global healthcare spending is expected to increase dramatically to more than $10 trillion by 2022, driven primarily by an increase in spending on data that will increase value and create a sustainable culture.
Indivior launched a copycat version of the opioid addiction drug Suboxone in the U.S., one day after a court decision cleared the way for rivals to market generic forms of the blockbuster medicine.
Intercept Pharmaceuticals Inc. said the treatment obeticholic acid (OCA) showed an improvement in scarring on the organ in patients with a progressive fatty liver disease.
Denmark’s H. Lundbeck and Japan’s Otsuka Pharmaceutical announced that the antipsychotic drug Rexulti (brexpiprazole) failed to meet the primary endpoint in two Phase III clinical studies to treat manic episodes in patients with bipolar I disorder.
Teva Pharmaceutical Industries forecast lower revenue and profit for 2019, missing analysts’ expectations, as the company faces generic competition for two key branded drugs.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Gilead Sciences Inc. said a late-stage study for selonsertib aimed at treating the progressive fatty liver disease NASH failed to meet the key experimental drug’s main goal, sending the company’s shares down 4.6 percent.
Eli Lilly embraced a U.S. government proposal to end a decades-old system of rebates drugmakers make to industry middlemen.
GlaxoSmithKline bolstered the company’s cancer drug development pipeline, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Merck KGaA for the rights to a next-generation immunotherapy.
Roche aims to broaden the use of the Swiss drugmaker’s Kadcyla breast cancer treatment as rivals crowd into the market with biosimilar copies of the company’s older mainstay product Herceptin.